anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and systems for detecting contaminated fragments in a biological sample for cancer classification are disclosed. The system identifies multiple SNP site contamination markers and indel site contamination markers. The multiple SNP site contamination markers include at least two SNP sites within a threshold distance, having population haplotype frequency within a range of threshold frequencies, excluding guanine-adenine polymorphisms and/or cytosine-thymine polymorphisms, ensuring Hardy-Weinberg equilibrium, or any combination of the parameters above. The indel site contamination markers include indel sequences that are within a threshold length, having high complexity, having population haplotype frequency within a range of threshold frequencies, ensuring Hardy-Weinberg equilibrium, or any combination of the parameters above. The system identifies contamination markers for which the sample is homozygous. The system estimates the contamination level of the sample by identifying fragments having a haplotype that is different than the homozygous haplotype of the respective contamination marker site.
The present invention relates to an exercise motion measurement sensor system for monitoring rehabilitation exercise capable of wearing a sensor on each point of a shoulder, an elbow, and a wrist of an arm to be treated; measuring an exercise angle of the arm in real time by using each sensor while moving the arm; and recording the same in an application and displaying the same on a screen. The present invention effectively helps rehabilitation treatment of a patient; allows a doctor to monitor an amount of rehabilitation exercise and the exercise angle of the patient through the application; and helps accurate diagnosis for each type of the rehabilitation exercise performed by the patient. Since the patient accurately checks an arm exercise angle, a rehabilitation period is shortened by allowing the patient to do the rehabilitation exercise harder to improve the exercise angle. The doctor objectively checks whether or not the patient properly did the rehabilitation exercise by inquiring an arm exercise angle record of the patient, an amount of exercise, and a pain level recorded in the application. Therefore, the present invention facilitates accurate diagnosis and prescription for a rehabilitation treatment patient. The present invention comprises: an operation sensing unit; an angle calculating unit; a managing unit; and a displaying unit.
BACKGROUND: Alpha 1 Antitrypsin Deficiency (AATD) is a largely underrecognized genetic condition characterized by low Alpha 1 Antitrypsin (AAT) serum levels, resulting from variations in SERPINA1. Many individuals affected by AATD are thought to be undiagnosed, leading to poor patient outcomes. The Z (c.1096G > A; p.Glu366Lys) and S (c.863A > T; p.Glu288Val) deficiency variants are the most frequently found variants in AATD, with the Z variant present in most individuals diagnosed with AATD. However, there are many other less frequent variants known to contribute to lung and/or liver disease in AATD. To identify the most common rare variants associated with AATD, we conducted a systematic literature review with the aim of assessing AATD variation patterns across the world.
METHODS: A systematic literature search was performed to identify published studies reporting AATD/SERPINA1 variants. Study eligibility was assessed for the potential to contain relevant information, with quality assessment and data extraction performed on studies meeting all eligibility criteria. AATD variants were grouped by variant type and linked to the geographical region identified from the reporting article.
RESULTS: Of the 4945 articles identified by the search string, 864 contained useful information for this study. Most articles came from the United States, followed by the United Kingdom, Germany, Spain, and Italy. Collectively, the articles identified a total of 7631 rare variants and 216 types of rare variant across 80 counties. The F (c.739C > T; p.Arg247Cys) variant was identified 1,281 times and was the most reported known rare variant worldwide, followed by the I (c.187C > T; p.Arg63Cys) variant. Worldwide, there were 1492 Null/rare variants that were unidentified at the time of source article publication and 75 rare novel variants reported only once.
CONCLUSION: AATD goes far beyond the Z and S variants, suggesting there may be widespread underdiagnosis of patients with the condition. Each geographical region has its own distinctive variety of AATD variants and, therefore, comprehensive testing is needed to fully understand the true number and type of variants that exist. Comprehensive testing is also needed to ensure accurate diagnosis, optimize treatment strategies, and improve outcomes for patients with AATD.
Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
Hydrochlorothiazide is well absorbed (65% to 75%) following oral administration. Absorption of hydrochlorothiazide is reduced in patients with congestive heart failure.

Peak plasma concentrations are observed within 1 to 5 hours of dosing, and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg. Plasma concentrations are linearly related to the administered dose. Concentrations of hydrochlorothiazide are 1.6 to 1.8 times higher in whole blood than in plasma. Binding to serum proteins has been reported to be approximately 40% to 68%. The plasma elimination half-life has been reported to be 6 to 15 hours. Hydrochlorothiazide is eliminated primarily by renal pathways. Following oral doses of 12.5 to 100 mg, 55% to 77% of the administered dose appears in urine and greater than 95% of the absorbed dose is excreted in urine as unchanged drug. In patients with renal disease, plasma concentrations of hydrochlorothiazide are increased and the elimination half-life is prolonged.

When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.

Pharmacodynamics:

Acute antihypertensive effects of thiazides are thought to result from a reduction in blood volume and cardiac output, secondary to a natriuretic effect, although a direct vasodilatory mechanism has also been proposed. With chronic administration, plasma volume returns toward normal, but peripheral vascular resistance is decreased. The exact mechanism of the antihypertensive effect of hydrochlorothiazide is not known.

Thiazides do not affect normal blood pressure. Onset of action occurs within 2 hours of dosing, peak effect is observed at about 4 hours, and activity persists for up to 24 hours.

Clinical Studies:

In an 87 patient 4-week double-blind, placebo controlled, parallel group trial, patients who received hydrochlorothiazide capsules, USP had reductions in seated systolic and diastolic blood pressure that were significantly greater than those seen in patients who received placebo. In published placebo-controlled trials comparing 12.5 mg of hydrochlorothiazide to 25 mg, the 12.5 mg dose preserved most of the placebo-corrected blood pressure reduction seen with 25 mg.
PURPOSE:To provide a skin cosmetic obtained by mixing a specific amount of a mixture of the extracts of lemon and eucalyptus, etc. at a specific ratio of a cosmetic base, and exhibiting beautifying effect free from side effects, eliminating the stimulation to the skin and preventing the roughening of the skin. CONSTITUTION:Lemon is mixed with eucalyptus and/or sage having astringency, etc. at a ratio of 3:7-7:3, and the mixture is dissolved in a solvent. Only the solvent is distilled off from the extract in vacuum to obtain an extract free from degradation, in high yield. The extract is added to a cosmetic base in an amount of >=1wt%. The lemon extract has excellent fragrance as well as the activity to balance the activity to form collagen, and is effective to smoothen the skin and give beautifying and astringent effect to the skin. EFFECT:The amount of the compounded perfumery added to the cosmetic can be decreased without necessitating the addition of a chemical antiseptic, taking advantage of the antiseptic effect of cineole existing in the extract of sage, etc.
PCT No. PCT/EP93/00029 Sec. 371 Date Oct. 18, 1993 Sec. 102(e) Date Oct. 18, 1993 PCT Filed Jan. 9, 1993 PCT Pub. No. WO93/16678 PCT Pub. Date Sep. 2, 1993.The process of dyeing hair includes uniformly applying to a strip of skin adjoining the hair line of the hair to be dyed a protective composition containing 27 to 50 percent by weight polyethylene glycol having an average molecular weight of 2,700 to 7,500; 7 to 14 percent by weight hydrogenated castor oil, ethoxylated with 40 to 60 moles of ethylene oxide; 28 to 42 percent by weight glycerin and/or ethyl hexanediol and/or polyethylene glycol having a molecular weight of 100 to 300; at least one standard cosmetic additive; and 0 to 18 percent by weight water; to protect the strip of the skin from coloring when dyeing or tinting hair; then treating the hair to be dyed with the hair dye; and after the treating of the hair with the hair dye, subsequently rinsing or rinsing and shampooing the hair.
An article is provided including composition of 0.5 to 15 total weight percent of a surfactant. The surfactant is a non-ionic surfactant, an anionic surfactant, or a combination thereof. The composition also includes 0.01 to 35 total weight percent of solvent including a microemulsion, a carboxylic acid ester based ketal ester solvent, or a combination thereof. 0.1 to 10 total weight percent of at least one emollient, and 60 to 99.3 total weight percent of water also being present. The resultant composition has total volatile organic content (VOC) composition of less than 2 total weight percent and as a result, the composition is more environmental benign and less irritating to skin than conventional waterless hand cleaners. The composition impregnated into a substrate of a towel presenting two opposed surfaces, the substrate having pores for absorbing and retaining the composition.
A health state estimating device 10 includes an acquiring unit 40 and a control unit 42. The acquiring unit 40 acquires gas information. The gas information is based on a signal output by a sensor unit during a period in which a first gas is being supplied to the sensor unit, and a signal output by the sensor unit during a period in which a second gas is being supplied to the sensor unit. The sensor unit outputs a signal having a signal value corresponding to the concentration of a specific gas. At least one of the acquisition position and the acquisition period differ between the first gas and the second gas. A control unit 39 generates health information on the basis of the gas information.
The effectiveness of DUVYZAT for the treatment of Duchenne muscular dystrophy (DMD) was evaluated in a randomized, double-blind, placebo-controlled 18-month study (Study 1; NCT02851797). A total of 179 patients were randomized 2:1 to receive either DUVYZAT (n = 118) or placebo (n = 61). A weight-based dose regimen was applied [see Dosage and Administration (2.2)]. The study included male patients 6 years of age and older with a confirmed diagnosis of DMD who were ambulatory and on a stable dosage of corticosteroids. At baseline, patients had a mean age of 9.8 years, 90% were White, 3% were Asian, 3% were Black.

The primary endpoint was the change from baseline to Month 18 in 4-stair climb (4SC) time for DUVYZAT compared to placebo. The 4SC is a measure of muscle function that tests the time it takes to climb 4 stairs. A secondary efficacy endpoint was change from baseline to Month 18 in physical function as assessed by the North Star Ambulatory Assessment (NSAA).

The primary analysis population was based on a prespecified range of baseline muscle fat fraction as determined by MR spectroscopy. Patients treated with DUVYZAT showed statistically significant less decline in the 4-stair climb compared to placebo (see Table 4). Patients treated with givinostat experienced less worsening on the NSAA compared to placebo, which was nominally significant but not statistically significant based on the prespecified multiplicity adjustment.
The invention provides a pharmaceutical composition for preventing and/or treating cancer, a preparation method and application thereof, and belongs to the field of chemical medicine. The invention firstly provides application of a compound shown as a formula I, or a salt or isomer thereof in preparing a p38 kinase inhibitor. Also provided are compounds of formula I for use in combination with a tumor immunotherapy medicament for the prevention and/or treatment of cancer. The compound of formula I is predominantly panatinib. The research of the invention finds that panatinib can reduce the activity of p38 alpha kinase, remarkably reduce the phosphorylation level of STAT1, reduce the expression of CXCL1 and CXCL2 by tumor cells, and reduce the direction of MDSCsThe migration and infiltration of the tumor part weaken the immunosuppressive effect of the tumor part on the tumor microenvironment, finally inhibit the growth and migration of tumor cells and play a role in preventing or treating cancers. In addition, the combination of the panatinib and an antibody drug for blocking a PD-1/PD-L1 immune checkpoint has an excellent effect, has a synergistic effect on tumor resistance, and has a good application prospect.
Risk Summary

Based on its mechanism of action and findings in animals, Azacitidine can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no data on the use of azacitidine in pregnant women. Azacitidine was teratogenic and caused embryo-fetal lethality in animals at doses lower than the recommended human daily dose (see Data). Advise pregnant women of the potential risk to the fetus. 

The background rate of major birth defects and miscarriage is unknown for the indicated population. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. 

Data

Animal Data

Early embryotoxicity studies in mice revealed a 44% frequency of intrauterine embryonal death (increased resorption) after a single IP (intraperitoneal) injection of 6 mg/m² (approximately 8% of the recommended human daily dose on a mg/m² basis) azacitidine on gestation day 10. Developmental abnormalities in the brain have been detected in mice given azacitidine on or before gestation day 15 at doses of ~3-12 mg/m² (approximately 4%-16% the recommended human daily dose on a mg/m² basis). 

In rats, azacitidine was clearly embryotoxic when given IP on gestation days 4-8 (postimplantation) at a dose of 6 mg/m² (approximately 8% of the recommended human daily dose on a mg/m² basis), although treatment in the preimplantation period (on gestation days 1-3) had no adverse effect on the embryos. Azacitidine caused multiple fetal abnormalities in rats after a single IP dose of 3 to 12 mg/m² (approximately 8% the recommended human daily dose on a mg/m² basis) given on gestation day 9, 10, 11 or 12. In this study azacitidine caused fetal death when administered at 3-12 mg/m² on gestation days 9 and 10; average live animals per litter was reduced to 9% of control at the highest dose on gestation day 9. Fetal anomalies included: CNS anomalies (exencephaly/encephalocele), limb anomalies (micromelia, club foot, syndactyly, oligodactyly), and others (micrognathia, gastroschisis, edema, and rib abnormalities).
Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
Pharmaceutical for the treatment of hypertonia contains selenium and conventional auxilliaries and carriers. The selenium can be present as an inorganic and/or organic cpd. Sodium selenite is the pref. inorganic cpd., while pref. organic cpds. are selenium yeast, selenium contg. algae, selenomethionine and/or selenocysteine. Pref. the daily dose of Se is 50-150 micrograms. USE/ADVANTAGE - The pharmaceutical can be used in the treatment of hypertonia (esp. primary hypertonia), while at the same time conpensating for selenium deficiency, one of the symptoms of hypertonia. Selenium is a trace element essential to humans and protects against various forms of liver necroses. It is a component of glutathione peroxidase, which protects red blood cells from peroxides.
JYLAMVO is supplied as a clear yellow oral solution that contains 2 mg of methotrexate per mL. It is packaged in an amber type III glass bottle with tamper evident child-resistant closure (polypropylene with expanded polyethylene liner) containing 60 mL of oral solution.

Each pack contains one bottle, a low-density polyethylene (LDPE) bottle adaptor and a 10 mL white polypropylene dosing syringe (with major graduations at every 1 mL and minor graduations at every 0.25 mL) (NDC 81927-204-01).

Store JYLAMVO at 20°C to 25°C (68°F to 77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

In Use storage conditions: Store JYLAMVO at room temperature 20°C to 25°C (68°F to 77°F). Keep the bottle tightly closed. After first opening, discard any unused medicine after 3 months.

JYLAMVO is a hazardous drug. Follow applicable special handling and disposal procedures.1
In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Mosunetuzumab is a CD20xCD3 T-cell-engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator assessment, after an overall median follow-up of 3.5 years in patients with relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphoma (iNHL/aNHL) from the dose-escalation stage of a phase I/II study of mosunetuzumab (ClinicalTrials.gov identifier: NCT02500407). Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved a complete or partial response to mosunetuzumab. Median duration of response (DoR) in patients with iNHL for all responders was 23.2 months (95% CI, 13.8 to not estimable [NE]), but was not reached in complete responders (95% CI, 21.0 to NE). After a median time on study of 38.9 months, no relapses were observed beyond 26 months in complete responders. In patients with aNHL, median DoR for all responders was 7.8 months (95% CI, 4.6 to 22.8). Among 12 complete responders who progressed postmosunetuzumab treatment and were retreated with mosunetuzumab, 83.3% had an objective response and 58.3% achieved a second complete response. Our study reports the longest follow-up using bispecific antibodies in patients with B-cell non-Hodgkin lymphoma and demonstrates that mosunetuzumab can mediate durable remissions with time-limited treatment.
Rationale: Small airway disease is an important pathophysiological feature of chronic obstructive pulmonary disease (COPD). Recently, "pre-COPD" has been put forward as a potential precursor stage of COPD that is defined by abnormal spirometry findings or significant emphysema on computed tomography (CT) in the absence of airflow obstruction. Objective: To determine the degree and nature of (small) airway disease in pre-COPD using microCT in a cohort of explant lobes/lungs. Methods: We collected whole lungs/lung lobes from patients with emphysematous pre-COPD (n = 10); Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I (n = 6), II (n = 6), and III/IV (n = 7) COPD; and controls (n = 10), which were analyzed using CT and microCT. The degree of emphysema and the number and morphology of small airways were compared between groups, and further correlations were investigated with physiologic measures. Airway and parenchymal pathology was also validated with histopathology. Measurements and Main Results: The numbers of transitional bronchioles and terminal bronchioles per milliliter of lung were significantly lower in pre-COPD and GOLD stages I, II, and III/IV COPD compared with controls. In addition, the number of alveolar attachments of the transitional bronchioles and terminal bronchioles was also lower in pre-COPD and all COPD groups compared with controls. We did not find any differences between the pre-COPD and COPD groups in CT or microCT measures. The percentage of emphysema on CT showed the strongest correlation with the number of small airways in the COPD groups. Histopathology showed an increase in the mean chord length and a decrease in alveolar surface density in pre-COPD and all GOLD COPD stages compared with controls. Conclusions: Lungs of patients with emphysematous pre-COPD already show fewer small airways and airway remodeling even in the absence of physiologic airway obstruction.
Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation of extracellular cGMP has been associated with a decrease in the activity of pain-sensing nerves in animal models of visceral pain. Elevation of intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, plecanatide has been shown to increase fluid secretion into the gastrointestinal (GI) tract, accelerate intestinal transit, and cause changes in stool consistency.

In an animal model of visceral pain, plecanatide reduced abdominal muscle contractions, a measure of intestinal pain.
The present invention relates to GLP-1 analogs and derivatives having Trp at a position corresponding to position 8 of GLP-1 (7-37), and pharmaceutical uses thereof, e.g. in the treatment of type 2 diabetes. Such Trp8 compounds are extremely stable to DPP-IV degradation while retaining the ability to bind to and activate the GLP-1 receptor. Such derivatives have one or two substituents (P-L) attached to the Lys residue of the GLP-1 analogue via an optional branching group (B), wherein P is an elongating moiety, such as a fatty diacid, and L is a linker consisting of one or more linker elements, such as 8-amino-3, 6-dioxaoctanoic acid. Examples of compounds of the invention include liraglutide and 8W variants of dolraglutide. The invention also relates to a method for the fully recombinant production of 8W GLP-1 analogues and derivatives which is simpler and therefore more economical to produce than known GLP-1 analogues stabilised by DPP-IV comprising one or more non-coding amino acids.